Details

Autor(en) / Beteiligte

• Ius, Fabio
• Aburahma, Khalil
• Boethig, Dietmar
• Salman, Jawad
• Sommer, Wiebke
• Draeger, Helge
• Poyanmehr, Reza
• Avsar, Murat
• Siemeni, Thierry
• Bobylev, Dmitry
• Optenhoefel, Joerg
• Wiesner, Olaf
• Greer, Mark
• Schwerk, Nicolaus
• Hoeper, Marius M.
• Welte, Tobias
• Haverich, Axel
• Kuehn, Christian
• Warnecke, Gregor
• Gottlieb, Jens
• Tudorache, Igor

Titel

Long-term outcomes after intraoperative extracorporeal membrane oxygenation during lung transplantation

Ist Teil von

• The Journal of heart and lung transplantation, 2020-09, Vol.39 (9), p.915-925

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2020

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• Over the past decade, extracorporeal membrane oxygenation (ECMO) has replaced cardiopulmonary bypass (CPB) for cardiopulmonary support during lung transplantation at our institution. In this study, we present our experience using intraoperative ECMO in isolated lung transplantation and evaluate its impact on long-term graft function and survival. All patients undergoing isolated lung transplantation with or without ECMO support between January 2010 and June 2019 were evaluated. Patients transplanted using CPB were excluded. Peri-operative and follow-up results from our database and patient charts were analyzed. Follow-up continued until September 1, 2019 (median, 3.34 years). In total, 311 of 1,161 lung transplant recipients (27%) received intraoperative ECMO, with 24 (2%) patients further requiring CPB. None of the remaining 826 (71%) patients required intraoperative cardiopulmonary support. ECMO patients exhibited higher pre-transplant surgical risk profiles and endured more complicated early post-operative courses than those without ECMO (in-hospital mortality, 10.9% vs 2.3%; p < 0.001). Inevitably, this resulted in poorer overall graft survival among ECMO recipients (p = 0.0025). However, correcting for patients surviving to hospital discharge, no difference in survival between groups was observed (5-year survival, 71% vs 72%; p = 0.56). Similarly, freedom from chronic lung allograft dysfunction, biopsy-confirmed cellular rejection, or need for pulsed-steroid therapy did not differ between the groups (p = 0.99, p = 0.78, and p = 0.93, respectively). Compared with patients not requiring cardiopulmonary support, ECMO recipients endured a more complicated peri-operative and early post-operative course. However, among those surviving to hospital discharge, no differences in long-term complications or outcomes were observed.